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EDITORIAL

Autosomal Dominant Polycystic Disease:
More Than Just Empty Space

I

n this issue of Advances in Chronic Kidney Disease, we focus on autosomal dominant polycystic kidney disease (ADPKD), the foremost
heritable form of kidney failure that eventuates in ESRD and a disorder marked by cysts
that are generally ‘‘empty’’ by ultrasonography. Treating ADPKD has always been difficult because sufficient quantitative methods
to extrapolate disease prognosis were wanting. Phenotypic variability and the imprecision with which one could predict the onset
of ESRD frustrated the clinician. Meanwhile,
scientific inquiry into the pathogenesis of
ADPKD continued and has recently produced
a story that has plausibly reconciled some of
the clinical conundra.
ADPKD is caused by dominant genetic
transmission of either of 2 defective genes,
PKD1 or PKD2. Generally, PKD1-responsible
disease is more severe than PKD2-associated
disease; however, there is much phenotypic
heterogeneity. In this regard, unusually mild
cases of ADPKD may be attributed to the transmission of so-called ‘‘hypomorphic’’ alleles (ie,
those that have retained partial activity).
Cystogenesis proceeds consequent to damage of the ‘‘good’’ unaffected copy of the affected gene. Thus, at the genetic locus, the
disorder behaves as a recessive disorder
consequent to somatic mutation. This ‘‘second
hit’’ hypothesis recapitulates the original
multimutation conceptualization of cancer
generation by Nordling1 and its subsequent
expansion and popularization by Knudson
in his work regarding oncogenic transformation in retinoblastoma2.

Defects of the polycystin-1 and polycystin-2
gene products of, respectively, ADPKD1 and
ADPKD2, both of which localize to the cilium,
disrupt normal cation-signaling pathways of
the cell. Hence, cyst formation is initiated
with inexorable enlargement, but the type 2
genotype generally manifests itself as a less severe phenotype. Indeed, the results from the
Consortium of Radiological Imaging Study
of ADPKD trial inform us that the larger the
cyst mass or renal volume, the worse the prognosis, irrespective of whether the cysts derive
from a ADPKD1 or ADPKD2 gene defect, the
latter of which showed lesser total and kidney
cyst volumes in comparison with their
ADPKD1 counterparts. In addition, it is the
amount of empty cyst space indicative of the
absence of functional renal parenchymal
mass that correlates best with prognosis.
ADPKD has induced as much uncertainty
and ambiguity of practice than nearly any
other kidney disorder. Obfuscation by the
presence of 2 genotypes has been profound
in terms of capably communicating with
afflicted persons their future relationship
between ADPKD and progressive CKD. The
questions that have been repeatedly brought
forth for the past several decades include the
following.
1. Screening: Who has the disease and who
should be screened within a family?
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What are the most cost-effective screening tests? Should patients be screened
for concurrent liver disease, cardiac
valvular anomalies, or intracranial
aneurysms?
Symptoms: Is the back pain from
ADPKD? Should a headache in an
ADPKD patient immediately prompt
suspicion for an intracranial aneurysm?
Is bloody urine attributable to cyst rupture and hemorrhage, a urinary tract infection, or a neoplasm? How and when
should one limit one’s activity profile?
Prognostic factors: What influences the
worsening of disease? Is the serum creatinine, the blood pressure, or the protein
most important? If kidney failure occurs,
is the prognosis different in the ADPKD
patient?
Management: Should intractable pain
from enlarging cysts be treated with narcotics? What is the best antibiotic for urinary tract infections in ADPKD? Is the
anemia of CKD the same in ADPKD as
it is in most other types of CKD? Are
radiocontrast procedures or gadolinium-based magnetic resonance imaging studies advisable for more detailed
evaluation? Are there evidence-based
methods to retard the progression of
CKD in ADPKD patients? Is there
a more optimal menu of therapeutic
agents for ADPKD? Is peritoneal dialysis strictly forbidden?
Clinical trials: What investigations are
ongoing, and what are the preliminary

results? Are there practical and clinical
extensibilities of any of the trials to
date?
To resolve these issues, the Guest Editors
have compiled a tight package of manuscripts
that resolves in part many of the vexing questions that have plagued basic scientists and
clinical nephrologists who have investigated
and/or treated ADPKD. The materials presented within this brief compendium serve
as guideposts for the practitioner who consults upon and manages patients with
ADPKD.
To summarize, the cysts of ADPKD are not
emblematic of nothingness, but they are dynamic and proliferative structures that we
must contend with. They represent much
more than just empty space. Perhaps now,
given the emergence of salutary therapies,
guided by current explorations into the pathobiology of cysts and the results of clinical
trials, we can, for the first time, offer a more
palatable menu of therapies for ADPKD
patients that differs from the expectant
strategy to which we had heretofore become
accustomed.
Jerry Yee, MD
Editor
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